NAD Precursor Combo Tested to Boost Muscle Mitochondria in Elderly Adults
Maastricht University investigated whether NA, NAM, and tryptophan together could restore mitochondrial function in physically compromised older adults.
Summary
As we age, mitochondrial function in skeletal muscle declines, contributing to fatigue, weakness, and reduced physical capacity. NAD+ is a critical molecule for mitochondrial energy production, and its levels fall significantly with age. This terminated clinical trial from Maastricht University set out to test whether a combination of three NAD+ precursors — nicotinic acid (NA), nicotinamide (NAM), and tryptophan — could reverse this decline in elderly individuals with compromised physical function. The trial measured outcomes related to mitochondrial function, energy metabolism, and physical performance. Although the study was terminated before completion, the research question remains highly relevant to the growing field of NAD+ supplementation and healthy aging. The trial's early termination limits conclusions but highlights ongoing challenges in translating promising preclinical NAD+ findings into robust human evidence.
Detailed Summary
Declining NAD+ levels are increasingly recognized as a central driver of the aging process, particularly in skeletal muscle where mitochondrial dysfunction contributes to sarcopenia, reduced energy, and loss of physical independence. Restoring NAD+ through dietary precursors has emerged as a promising strategy, but rigorous human trials — especially in vulnerable elderly populations — remain limited.
This clinical trial, registered at ClinicalTrials.gov (NCT03310034) and sponsored by Maastricht University, aimed to determine whether a combination of three NAD+ precursors — nicotinic acid (NA), nicotinamide (NAM), and tryptophan — could stimulate skeletal muscle mitochondrial function in physically compromised elderly participants. The multi-precursor approach is notable, as each compound feeds into NAD+ biosynthesis through distinct pathways, potentially offering synergistic effects compared to single-precursor strategies.
Primary outcomes focused on mitochondrial function and energy metabolism, with secondary measures of physical function. The study targeted a population with real-world clinical relevance: older adults whose physical capacity is already compromised, representing those most likely to benefit from mitochondrial-targeted interventions.
Unfortunately, the trial was terminated before completion, and no results are publicly available. The reasons for termination are not disclosed in the registry, which is a significant limitation. Early termination may reflect recruitment difficulties, safety signals, funding issues, or logistical challenges — all common in geriatric intervention trials.
Despite the lack of results, this trial underscores the scientific momentum behind NAD+ precursor research in aging. The choice of a precursor combination rather than a single agent like NMN or NR reflects an evolving understanding of NAD+ metabolism. Clinicians and researchers should note that while preclinical and some human data are encouraging, definitive evidence for NAD+ supplementation improving physical function in elderly populations remains elusive, and terminated trials like this one highlight the difficulty of generating that evidence.
Key Findings
- Trial tested a novel three-precursor NAD+ blend (NA, NAM, tryptophan) targeting skeletal muscle mitochondria in elderly adults.
- Study population was physically compromised elderly individuals — a high-need group rarely studied in NAD+ supplementation trials.
- Primary outcomes included mitochondrial function and energy metabolism, with physical function as a secondary endpoint.
- The trial was terminated before completion; no results are publicly available from this study.
- Multi-precursor NAD+ strategies may offer synergistic biosynthesis benefits over single-compound approaches like NMN or NR.
Methodology
This was a controlled interventional trial (Phase not specified) comparing a NAD+ precursor mixture (NA, NAM, tryptophan) against a control condition in physically compromised elderly participants. Outcomes spanned mitochondrial function, energy metabolism, and physical performance measures. The trial was registered in 2017 and sponsored by Maastricht University but was terminated prior to completion.
Study Limitations
The trial was terminated before completion, meaning no efficacy or safety results are available to inform clinical practice. The summary is based on the abstract and registry entry only — full protocol details, sample size, and reasons for termination are unknown. The absence of published results represents a significant gap in the evidence base for this intervention.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.